Jena/Deutschland | Dublin/USA,
27
October
2021
|
15:27
Europe/Amsterdam

ZEISS Introduces the Fully Integrated, Data-Driven Medical Ecosystem

The ZEISS Medical Ecosystem enables multiple layers of added value by connecting devices, data and applications to optimize clinical management of patients.

Summary

ZEISS today announced its new ZEISS Medical Ecosystem, a fully integrated environment where a combination of devices, data management, applications, and services drive continuous improvement of patient outcomes. This ecosystem distinctively combines unsurpassed ocular expertise with leading-edge digital technology enabling evidence-based decisions that assure more efficient delivery of the highest quality of care in a single and secure platform.

“At ZEISS, the core of our business strategy is shaping healthcare with new technologies in order to advance medicine,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “With the ZEISS Medical Ecosystem, we are uniquely positioned to drive the digital transformation of ophthalmology working with external partners, including customers, healthcare providers and digital innovators.”

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG
At ZEISS, the core of our business strategy is shaping healthcare with new technologies in order to advance medicine.
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG

“This fully-connected platform will continue to expand our integrated workflow solutions, adding value for the customer and enabling new ways to maximize clinical efficiency and performance,” said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. “The power of digital technologies, data management and a range of new applications will create an environment of connectivity, automation, artificial intelligence, and safe and efficient management of data, enabling improved results for patients. I truly believe that the digital ecosystem will provide opportunities to improve the efficiency of healthcare delivery and ultimately, quality of life for our customers’ patients.”

The ZEISS Medical Ecosystem makes digital adoption easy, providing one ecosystem connecting devices, data and applications that enable a streamlined workflow, clinical planning, education, and optimization of clinical procedures. It opens possibilities for the creation of new solutions, where data passes seamlessly from one ZEISS device to another using artificial-intelligence-powered applications and software tools.

“In our clinical environment, data management and efficient workflows can be a challenge,” said Ranya Habash, MD, distinguished surgeon and assistant professor of ophthalmology at the Bascom Palmer Eye Institute, where she also serves as medical director of technology innovation. “So combining new ZEISS technologies with our existing equipment, even from other providers, allows for more accessible data and helps me provide better care to my patients.”

With the ZEISS integrated portfolio of diagnostic and therapeutic devices supported by a cloud-based digital platform, the ZEISS Medical Ecosystem delivers value beyond the devices with a fully connected and integrated approach that is unsurpassed in the medical industry.

Boilerplate

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 6.3 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2020).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 12 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 34,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG (status: 31 March 2021).